BlackRock’s Entera Bio ENTX Stock Holding History

BlackRock’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-500	Closed	-$365	–	5608
2022 Q4	$365	Buy	+500	New	+$362	﹤0.01%	5683

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BlackRock's ENTX Position: Q1 2023 in Review

BlackRock sold out of Entera Bio (ENTX) in Q1 2023, closing a stake of 500 shares — an estimated $365 sold.

BlackRock first reported a position in ENTX in Q4 2022 and held it in 1 quarter. The position peaked at $365 in Q4 2022. 9 funds tracked by Wall St. Rank hold ENTX as of Q1 2023.

BlackRock reported no remaining Entera Bio position as of Q1 2023 after selling out during the quarter.
BlackRock sold 500 Entera Bio shares in Q1 2023, an estimated $365.
BlackRock first reported a position in Entera Bio in Q4 2022 and held it in 1 quarter.
BlackRock's Entera Bio position peaked at $365 in Q4 2022.
9 funds tracked by Wall St. Rank held Entera Bio as of Q1 2023.

Based on BlackRock's 13F filing for Q1 2023, filed 12 May 2023.